Trilaciclib to prevent bone marrow side effects from ADC chemo
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a drug called Trilaciclib to see if it can prevent low blood cell counts caused by a type of chemotherapy called topoisomerase I inhibitor ADCs. If you are getting this kind of chemo, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with a solid tumor cancer.
- Your doctor plans to treat you with a specific type of ADC chemo (like Regucitinib or Gosatuzumab).
- You are in fairly good health (ECOG score 0-2) and expected to live at least 12 weeks.
- Your blood cell counts, liver, kidney, and heart function are within safe limits.
- You have not used certain blood cell boosters or blood transfusions in the 2 weeks before starting.
- You do not have a history of lung inflammation (interstitial pneumonia) or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called trilaciclib, given along with standard chemotherapy (etoposide plus cisplatin or carboplatin) and radiation. The goal is to see if trilaciclib can help protect your bone marrow from the side effects of treatment.
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests a drug called trilaciclib, given before chemotherapy to protect your bone marrow (where blood cells are made). It is for people with advanced bile duct or pancreatic cancer who are about to start chemotherapy.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests a drug called trilaciclib to see if it can protect your blood cell counts during treatment for head and neck cancer that has come back or spread. You must not have had chemotherapy before for this stage of cancer.
Hear when a new Tumor Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.